{"id":"conventional-strategy-aspirin","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Gastrointestinal bleeding or ulceration"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"2-5","effect":"Nausea"},{"rate":"<1","effect":"Hemorrhagic stroke (at higher doses)"},{"rate":"<1","effect":"Allergic reactions (including bronchospasm in aspirin-sensitive individuals)"},{"rate":"rare","effect":"Renal impairment (chronic use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin acetylates serine residues on COX-1 and COX-2 enzymes, permanently blocking their catalytic activity. This prevents the synthesis of thromboxane A2 in platelets, which is essential for platelet activation and clot formation, thereby reducing thrombotic events. Additionally, aspirin reduces prostaglandin-mediated inflammation and pain signaling.","oneSentence":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of thromboxane A2 and other prostaglandins to decrease platelet aggregation and inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:31:18.496Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myocardial infarction prevention and secondary prevention"},{"name":"Ischemic stroke prevention"},{"name":"Transient ischemic attack (TIA) prevention"},{"name":"Unstable angina"},{"name":"Mild to moderate pain and fever"},{"name":"Rheumatoid arthritis and other inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":"Left Main Coronary Artery Stenosis","enrollment":828},{"nctId":"NCT02520921","phase":"PHASE4","title":"Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-06-13","conditions":"Diabetes Mellitus, Acute Coronary Syndrome, Coronary Artery Disease","enrollment":2484},{"nctId":"NCT04755387","phase":"PHASE4","title":"Ticagrelor De-escalation Strategy in AMI Patients","status":"RECRUITING","sponsor":"Dong-A University","startDate":"2023-03-27","conditions":"Acute Myocardial Infarction","enrollment":2312},{"nctId":"NCT03465644","phase":"PHASE4","title":"TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI","status":"COMPLETED","sponsor":"Duk-Woo Park, MD","startDate":"2019-02-12","conditions":"Coronary Stenoses","enrollment":2018},{"nctId":"NCT05066789","phase":"PHASE4","title":"CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2022-01-17","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT03003325","phase":"PHASE2","title":"The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV","status":"COMPLETED","sponsor":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","startDate":"2017-02-02","conditions":"Polycythemia Vera","enrollment":127},{"nctId":"NCT05418556","phase":"PHASE4","title":"Tailored Versus Coventional AntiPlaTelet Strategy Intended After OPTIMIZEd Drug Eluting Stent","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-10-21","conditions":"Coronary Artery Disease","enrollment":3944},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06084000","phase":"NA","title":"STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-10-15","conditions":"Drug-coated Balloon, Drug-eluting Stent, De Novo Stenosis","enrollment":2700},{"nctId":"NCT02601157","phase":"PHASE4","title":"Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-01-18","conditions":"Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction","enrollment":2173},{"nctId":"NCT04619927","phase":"PHASE4","title":"Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2021-03-01","conditions":"Peripheral Arterial Disease","enrollment":2276},{"nctId":"NCT04504864","phase":"PHASE4","title":"Low-dose Aspirin Therapy in Patients With Ischemic Stroke and Microbleeds","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2020-10-01","conditions":"Ischemic Stroke","enrollment":400},{"nctId":"NCT01103440","phase":"PHASE2","title":"Aspirin Resistance and Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2007-04","conditions":"Stable Angina","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":169,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Conventional strategy Aspirin","genericName":"Conventional strategy Aspirin","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of thromboxane A2 and other prostaglandins to decrease platelet aggregation and inflammation. Used for Acute myocardial infarction prevention and secondary prevention, Ischemic stroke prevention, Transient ischemic attack (TIA) prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}